C-FOS suppresses ovarian cancer progression by changing adhesion

British Journal of Cancer

Volumn 110, Issue 3, 2014, Pages 753-763

  Oliveira Ferrer, L ^a   Roßler K ^a   Haustein, V ^a   Schroder C ^a   Wicklein, D ^a   Maltseva, D ^b   Khaustova, N ^b   Samatov, T ^b   Tonevitsky, A ^c   Mahner, S ^a   Janicke F ^a   Schumacher, U ^a   Milde Langosch, K ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b SRC Bioclinicum   (Russian Federation)

^c INSTITUTE OF GENERAL PATHOLOGY AND PATHOPHYSIOLOGY   (Russian Federation)

Author keywords

adhesion; apoptosis; c FOS; metastasis; ovarian cancer cells

Indexed keywords

CAMPTOTHECIN; COLLAGEN TYPE 4; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FIBRONECTIN; LAMININ; VITRONECTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CELL ADHESION; CELL MIGRATION; CELL PROLIFERATION; CIRCULATING TUMOR CELL; CONTROLLED STUDY; EXTRACELLULAR MATRIX; FEMALE; GENE EXPRESSION; GENE OVEREXPRESSION; GLYCOSYLATION; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG METASTASIS; MESOTHELIUM CELL; MICROMETASTASIS; MOUSE; NONHUMAN; ONCOGENE C FOS; OVARY CANCER; PHENOTYPE; PRIORITY JOURNAL; SHEAR STRESS; TUMOR INVASION; UPREGULATION;

ANIMALS; APOPTOSIS; CARCINOGENESIS; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DISEASE PROGRESSION; EXTRACELLULAR MATRIX; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; NEOPLASM INVASIVENESS; NEOPLASTIC CELLS, CIRCULATING; OVARIAN NEOPLASMS; PROTO-ONCOGENE PROTEINS C-FOS;

EID: 84893753825     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.774     Document Type: Article

References (50)

1. Angel P, Karin M (1991) The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. Biochim Biophys Acta 1072(2-3): 129-157.
2. Appierto V, Villani MG, Cavadini E, Lotan R, Vinson C, Formelli F (2004) Involvement of c-Fos in fenretinide-induced apoptosis in human ovarian carcinoma cells. Cell Death Differ 11(3): 270-279.
3. Barthel SR, Gavino JD, Descheny L, Dimitroff CJ (2007) Targeting selectins and selectin ligands in inflammation and cancer. Expert Opin Ther Targets 11(11): 1473-1491.
4. Dippel V, Milde-Langosch K, Wicklein D, Schumacher U, Altevogt P, Oliveira-Ferrer L, Janicke F, Schroder C (2012) Influence of L1-CAM expression of breast cancer cells on adhesion to endothelial cells. J Cancer Res Clin Oncol 139(1): 107-121.
5. Durchdewald M, Angel P, Hess J (2009) The transcription factor Fos: a Janus-type regulator in health and disease. Histol Histopathol 24(11): 1451-1461.
6. Gamberi G, Benassi MS, Bohling T, Ragazzini P, Molendini L, Sollazzo MR, Pompetti F, Merli M, Magagnoli G, Balladelli A, Picci P (1998) C-myc and c-fos in human osteosarcoma: prognostic value of mRNA and protein expression. Oncology 55: 556-563.
7. Gebauer F, Wicklein D, Stubke K, Nehmann N, Schmidt A, Salamon J, Peldschus K, Nentwich MF, Adam G, Tolstonog G, Bockhorn M, Izbicki JR, Wagener C, Schumacher U (2012) Selectin binding is essential for peritoneal carcinomatosis in a xenograft model of human pancreatic adenocarcinoma in pfp-/rag2-mice. Gut 62: 741-750.
8. Guinea-Viniegra J, Zenz R, Scheuch H, Jimenez M, Bakiri L, Petzelbauer P, Wagner EF (2012) Differentiation-induced skin cancer suppression by FOS, p53, and TACE/ADAM17. J Clin Invest 122(8): 2898-2910.
9. Hein S, Mahner S, Kanowski C, Löning T, Jänicke F, Milde-Langosch K (2009) Expression of Jun and Fos proteins in ovarian tumors of different malignant potential and in ovarian cancer cell lines. Oncol Rep 22(1): 177-183.
10. Hennigan RF, Hawker KL, Ozanne BW (1994) Fos-transformation activates genes associated with invasion. Oncogene 9(12): 3591-3600.
11. Iwanicki MP, Davidowitz RA, Ng MR, Besser A, Muranen T, Merritt M, Danuser G, Ince TA, Brugge JS (2011) Ovarian cancer spheroids use myosin-generated force to clear the mesothelium. Cancer Discov 1(2): 144-157.
12. Jänicke F, Pache L, Schmitt M, Ulm K, Thomssen C, Prechtl A, Graeff H (1994) Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plaminogen activator inhibitor type I. Cancer Res 54: 2527-2530.
13. Jin SP, Kim JH, Kim MA, Yang HK, Lee HE, Lee HS, Kim WH (2007) Prognostic significance of loss of c-fos protein in gastric carcinoma. Pathol Oncol Res 13(4): 284-289.
14. Jojovic M, Schumacher U (2000) Quantitative assessment of spontaneous lung metastases of human HT29 colon cancer cells transplanted into scid mice. Cancer Lett 152: 151-156.
15. Kalra N, Kumar V (2004) c-Fos is a mediator of the c-myc-induced apoptotic signaling in serum-deprived hepatoma cells via the p38 mitogen-activated protein kinase pathway. J Biol Chem 279(24): 25313-25319.
16. König H, Ponta H, Rahmsdorf U, Buscher M, Schonthal A, Rahmsdorf HJ, Herrlich P (1989) Autoregulation of fos: the dyad symmetry element as the major target of repression. EMBO J 8(9): 2559-2566.
17. Kustikova O, Kramerov D, Grigorian M, Berezin V, Bock E, Lukanidin E, Tulchinsky E (1998) Fra-1 induces morphological transformation and increases in vitro invasiveness and mobility of epithelioid adenocarcinoma cells. Mol Cell Biol 18: 7095-7105.
18. Lange T, Ullrich S, Muller I, Nentwich MF, Stubke K, Feldhaus S, Knies C, Hellwinkel OJ, Vessella RL, Abramjuk C, Anders M, Schroder-Schwarz J, Schlomm T, Huland H, Sauter G, Schumacher U (2012) Human prostate cancer in a clinically relevant xenograft mouse model: identification of beta(1,6)-branched oligosaccharides as a marker of tumor progression. Clin Cancer Res 18(5): 1364-1373.
19. Li YQ, Tao KS, Ren N, Wang YH (2005) Effect of c-fos antisense probe on prostaglandin E2-induced upregulation of vascular endothelial growth factor mRNA in human liver cancer cells. World J Gastroenterol 11(28): 4427-4430.
20. Liu G, Ding W, Liu X, Mulder KM (2006) c-Fos is required for TGFbeta1 production and the associated paracrine migratory effects of human colon carcinoma cells. Mol Carcinog 45(8): 582-593.
21. Liu G, Takano T, Matsuzuka H, Higashiyama T, Kuma K, Amino N (1999) Screening of specific changes in mRNAs in thyroid tumors by sequence specific differential display: decreased expression of c-Fos mRNA in papillary carcinoma. Endocr J 46: 459-466.
22. Mahner S, Baasch C, Schwarz J, Hein S, Wolber L, Janicke F, Milde-Langosch K (2008) C-Fos expression is a molecular predictor of progression and survival in epithelial ovarian carcinoma. Br J Cancer 99(8): 1269-1275.
23. Meinhold-Heerlein I, Bauerschlag D, Hilpert F, Dimitrov P, Sapinoso LM, Orlowska-Volk M, Bauknecht T, Park T-W, Jonat W, Jacobsen A, Sehouli J, Luttges J, Krajewski M, Krajewski S, Reed JC, Arnold N, Hampton GM (2005) Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential. Oncogene 24: 1053-1065.
24. Mejlvang J, Kriajevska M, Berditchevski F, Bronstein I, Lukanidin EM, Pringle JH, Mellon JK, Tulchinsky EM (2007) Characterization of E-cadherin-dependent and-independent events in a new model of c-Fos-mediated epithelial-mesenchymal transition. Exp Cell Res 313(2): 380-393.
25. Mikula M, Gotzmann J, Fischer A, Wolschek MF, Thallinger C, Schulte-Hermann R, Beug H, Mikulits W (2003) The proto-oncogene c-Fos negatively regulates hepatocellular tumorigenesis. Oncogene 22: 6725-6738.
26. Milde-Langosch K (2005) The Fos family of transcription factors and their role in tumourigenesis. Eur J Cancer 41(16): 2449-2461.
27. Miller DA, Curran T, Verma IM (1984) c-fos protein can induce cellular transformation: a novel mechanism of a cellular oncogene. Cell 36: 51-60.
28. Mochizuki Y, Nakanishi H, Kodera Y, Ito S, Yamamura Y, Kato T, Hibi K, Akiyama S, Nakao A, Tatematsu M (2004) TNF-alpha promotes progression of peritoneal metastasis as demonstrated using a green fluorescence protein (GFP)-tagged human gastric cancer cell line. Clin Exp Metastasis 21(1): 39-47.
29. Monzavi-Karbassi B, Stanley JS, Hennings L, Jousheghany F, Artaud C, Shaaf S, Kieber-Emmons T (2007) Chondroitin sulfate glycosaminoglycans as major P-selectin ligands on metastatic breast cancer cell lines. Int J Cancer 120(6): 1179-1191.
30. Murakami T, Mataki C, Nagao C, Umetani M, Wada Y, Ishii M, Tsutsumi S, Kohro T, Saiura A, Aburatani H, Hamakubo T, Kodama T (2000) The gene expression profile of human umbilical vein endothelial cells stimulated by tumor necrosis factor alpha using DNA microarray analysis. J Atheroscler Thromb 7(1): 39-44.
31. Na D, Lv ZD, Liu FN, Xu Y, Jiang CG, Sun Z, Miao ZF, Li F, Xu HM (2010) Transforming growth factor beta1 produced in autocrine/paracrine manner affects the morphology and function of mesothelial cells and promotes peritoneal carcinomatosis. Int J Mol Med 26(3): 325-332.
32. Nandy A, Jenatschke S, Hartung B, Milde-Langosch K, Bamberger AM, Gellersen B (2003) Genomic structure and transcriptional regulation of the human NAD\+-dependent 15-hydroxyprostaglandin dehydrogenase gene. J Mol Endocrinol 31(1): 105-121.
33. Oliveira-Ferrer L, Wellbrock J, Braig M, Klokow M, Hauschild J, Bokemeyer C, Fiedler W, Ergun S, Schuch G (2012) The metabolite 3-hydroxiglutaric acid effectively reduces glioblastoma growth in vivo by affecting the structural integrity of tumor vasculature. Cancer Lett 326(2): 161-167.
34. Richter U, Schroder C, Wicklein D, Lange T, Geleff S, Dippel V, Schumacher U, Klutmann S (2011) Adhesion of small cell lung cancer cells to E-and P-Selectin under physiological flow conditions: implications for metastasis formation. Histochem Cell Biol 135(5): 499-512.
35. Rüther U, Komitowski D, Schubert FR, Wagner EF (1989) c-Fos expression induces bone tumors in transgenic mice. Oncogene 4: 861-865.
36. Schröder C, Schumacher U, Müller V, Wirtz RM, Streichert T, Richter U, Wicklein D, Milde-Langosch K (2010) The transcription factor Fra-2 promotes mammary tumour progression by changing the adhesive properties of breast cancer cells. Eur J Cancer 46(9): 1650-1660.
37. Shafarenko M, Amanullah A, Gregory B, Liebermann DA, Hoffman B (2004) Fos modulates myeloid cell survival and differentiation and partially abrogates the c-Myc block in terminal myeloid differentiation. Blood 103(11): 4259-4267.
38. Shaulian E, Karin M (2001) AP-1 in cell proliferation and survival. Oncogene 20(19): 2390-2400.
39. Shimotsuma M, Kawata M, Hagiwara A, Takahashi T (1989) Milky spots in the human greater omentum. Macroscopic and histological identification. Acta Anat (Basel) 136(3): 211-216.
40. Silvestre DC, Gil GA, Tomasini N, Bussolino DF, Caputto BL (2010) Growth of peripheral and central nervous system tumors is supported by cytoplasmic c-Fos in humans and mice. PLoS One 5(3): e9544.
41. Strell C, Entschladen F (2008) Extravasation of leukocytes in comparison to tumor cells. Cell Commun Signal 6: 10.
42. Stübke K, Wicklein D, Herich L, Schumacher U, Nehmann N (2012) Selectin-deficiency reduces the number of spontaneous metastases in a xenograft model of human breast cancer. Cancer Lett 321(1): 89-99.
43. Tan DS, Agarwal R, Kaye SB (2006) Mechanisms of transcoelomic metastasis in ovarian cancer. Lancet Oncol 7(11): 925-934.
44. Tremblay PL, Huot J, Auger FA (2008) Mechanisms by which E-selectin regulates diapedesis of colon cancer cells under flow conditions. Cancer Res 68(13): 5167-5176.
45. Volm M, Koomägi R, Mattern J, Efferth T (2002) Expression profile of genes in non-small cell lung carcinomas from long-term surviving patients. Clin Cancer Res 8: 1843-1848.
46. von Andrian UH, Mackay CR (2000) T-cell function and migration. Two sides of the same coin. N Engl J Med 343(14): 1020-1034.
47. Welser-Alves JV, Boroujerdi A, Tigges U, Milner R (2011) Microglia use multiple mechanisms to mediate interactions with vitronectin; nonessential roles for the highly-expressed alphavbeta3 and alphavbeta5 integrins. J Neuroinflammation 8: 157.
48. Wen W, Iwakiri D, Yamamoto K, Maruo S, Kanda T, Takada K (2007) Epstein-Barr virus BZLF1 gene, a switch from latency to lytic infection, is expressed as an immediate-early gene after primary infection of B lymphocytes. J Virol 81(2): 1037-1042.
49. Workman P, Aboagye EO, Balkwill F, Balmain A, Bruder G, Chaplin DJ, Double JA, Everitt J, Farningham DA, Glennie MJ, Kelland LR, Robinson V, Stratford IJ, Tozer GM, Watson S, Wedge SR, Eccles SA (2010) Guidelines for the welfare and use of animals in cancer research. Br J Cancer 102(11): 1555-1577.
50. Zhang X, Zhang L, Yang H, Huang X, Otu H, Libermann TA, DeWolf WC, Khosravi-Far R, Olumi AF (2007) c-Fos as a proapoptotic agent in TRAILinduced apoptosis in prostate cancer cells. Cancer Res 67(19): 9425-9434.